Article Text

Download PDFPDF
Cats
Use of imatinib mesylate in a cat with gastrointestinal stromal tumour
  1. Sungjun Won,
  2. Yongbaek Kim and
  3. Junghee Yoon
  1. College of Veterinary Medicine and the Research Institute for Veterinary Science, Seoul National University, Seoul, Republic of Korea
  1. Correspondence to Dr Junghee Yoon; heeyoon{at}snu.ac.kr

Abstract

A two-year-old, Turkish Angora, neutered male cat was evaluated for acute onset of melena and anaemia. A mass was identified in the duodenum and was diagnosed as gastrointestinal stromal tumour (GIST) through immunohistochemistry. The cat developed suspected nephropathy after 12 months of imatinib treatment for GIST. Imatinib was discontinued, but the patient died after two months due to renal failure. GIST is a rare neoplasm in cats, and treatment with imatinib in feline GIST has not been previously reported.

  • imatinib mesylate
  • cat
  • gastrointestinal stromal tumor
  • gist
  • adverse effect
View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors Conception and design, acquisition of data, or analysis and interpretation of data: SW, YK, JY. Drafting the article or revising it critically for important intellectual content: SW, YK, JY. Final approval of the version published: SW, YK, JY.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement No additional data available.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.